Meyka AI API is live for developers.Start building.
Advertisement
Aytu BioPharma, Inc.

Aytu BioPharma, Inc. (AYTU) Stock Competitors & Peer Comparison

See (AYTU) competitors and their performances in Stock Market.

AYTUNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$2.25
$0.13(5.89%)
U.S. Market opens in 59h 2m
Advertisement

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
AYTU$2.14+2.39%17.3M-0.46-$4.61N/A
TAK$15.59+3.69%48.8B41.78$0.37+4.03%
TEVA$34.34+4.60%40.1B25.69$1.34N/A
HLN$9.10+4.30%39.9B17.96$0.50+2.16%
VTRS$16.04+3.05%18.5B-53.00-$0.30+3.01%
ITCI$131.87+0.00%14B-180.64-$0.73N/A
ELAN$24.53-0.18%12.3B-49.39-$0.50N/A
CTLT$63.48+0.00%11.5B-27.84-$2.28N/A
RDY$13.34+2.42%11B24.50$0.54+0.69%
RGC$20.81-12.38%11B-2216.00-$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

AYTU vs TAK Comparison June 2026

AYTU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AYTU stands at 17.3M. In comparison, TAK has a market cap of 48.8B. Regarding current trading prices, AYTU is priced at $2.14, while TAK trades at $15.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AYTU currently has a P/E ratio of -0.46, whereas TAK's P/E ratio is 41.78. In terms of profitability, AYTU's ROE is -1.49%, compared to TAK's ROE of +0.03%. Regarding short-term risk, AYTU is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for AYTU.Check TAK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions